Medicine
Tuesday, July 23, 2019
Second opinion | Immunotherapy in cancer treatment | BCBS | Complete Episode
Although his initial prognosis was 6 to 8 months, Ronald Eckert, MD, is thriving after a new phase 4 melanoma immunotherapy.
Orignal From:
Second opinion | Immunotherapy in cancer treatment | BCBS | Complete Episode
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment